Literature DB >> 32782349

Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.

Talha Badar1, Bryon D Johnson1, Mehdi Hamadani2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32782349     DOI: 10.1038/s41409-020-01029-4

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.

Authors:  Philipp Karschnia; Justin T Jordan; Deborah A Forst; Isabel C Arrillaga-Romany; Tracy T Batchelor; Joachim M Baehring; Nathan F Clement; L Nicolas Gonzalez Castro; Aline Herlopian; Marcela V Maus; Michaela H Schwaiblmair; Jacob D Soumerai; Ronald W Takvorian; Ephraim P Hochberg; Jeffrey A Barnes; Jeremy S Abramson; Matthew J Frigault; Jorg Dietrich
Journal:  Blood       Date:  2019-02-26       Impact factor: 22.113

Review 3.  Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  Talha Badar; Nirav N Shah
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

4.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Authors:  Juliane Gust; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; David Myerson; Luis F Gonzalez-Cuyar; Cecilia Yeung; W Conrad Liles; Mark Wurfel; Jose A Lopez; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Tahsin Özpolat; Kathleen R Fink; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Cancer Discov       Date:  2017-10-12       Impact factor: 39.397

5.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

6.  Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Authors:  David T Teachey; Michael R Bishop; David G Maloney; Stephan A Grupp
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

7.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Authors:  Michael Wang; Javier Munoz; Andre Goy; Frederick L Locke; Caron A Jacobson; Brian T Hill; John M Timmerman; Houston Holmes; Samantha Jaglowski; Ian W Flinn; Peter A McSweeney; David B Miklos; John M Pagel; Marie-Jose Kersten; Noel Milpied; Henry Fung; Max S Topp; Roch Houot; Amer Beitinjaneh; Weimin Peng; Lianqing Zheng; John M Rossi; Rajul K Jain; Arati V Rao; Patrick M Reagan
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

Review 8.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Authors:  Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-25       Impact factor: 5.742

9.  Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.

Authors:  Yongxian Hu; Jie Sun; Zhao Wu; Jian Yu; Qu Cui; Chengfei Pu; Bin Liang; Yi Luo; Jimin Shi; Aiyun Jin; Lei Xiao; He Huang
Journal:  J Hematol Oncol       Date:  2016-08-15       Impact factor: 17.388

  9 in total
  1 in total

1.  Neurological updates: neurological complications of CAR-T therapy.

Authors:  Emma C Tallantyre; Nia A Evans; Jack Parry-Jones; Matt P G Morgan; Ceri H Jones; Wendy Ingram
Journal:  J Neurol       Date:  2020-11-02       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.